Enveda
United States · Biotech · AI
Enveda uses AI to discover biologically active molecules from nature and develop them into small-molecule medicines for inflammatory and metabolic diseases.
Product and development
Enveda’s PRISM platform analyzes natural samples to identify the molecules they contain and understand what those molecules do biologically. AI, large-scale mass-spectrometry data and laboratory workflows help the company search natural chemistry at scale and select compounds for medicinal-chemistry development.
Enveda develops its discoveries as an internal therapeutic pipeline rather than selling only a discovery tool. Its clinical programs include ENV-294 for atopic dermatitis and asthma, ENV-308 for post-weight-loss maintenance, and ENV-6946 for inflammatory bowel disease; these candidates are in clinical development and are not approved medicines.
- Product focus
- AI-enabled natural-product drug discovery and clinical pipeline
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series E | $311M | Catalio Capital Management — LeadAlderline Group — ParticipantBaillie Gifford — ParticipantDigitalis Ventures — ParticipantDimension — ParticipantDurable Capital Partners — ParticipantFPV Ventures — ParticipantICONIQ — ParticipantKinnevik — ParticipantLifeforce Capital — ParticipantLightspeed — ParticipantLux Capital — ParticipantPremji Invest — ParticipantSurveyor Capital — ParticipantT. Rowe Price Investment Management — ParticipantTrue Ventures — Participant |